AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Lupin Ltd Capital/Financing Update 2023

Oct 16, 2023

61031_rns_2023-10-16_d2368ee1-3fab-47be-9aa7-d8cd24da5a20.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

==> picture [79 x 93] intentionally omitted <==

October 16, 2023

 BSE Limited

Department of Corporate Services, P. J. Towers, Dalal Street, Mumbai Samachar Marg, MUMBAI - 400 001.

National Stock Exchange of India Limited

Exchange Plaza, Bandra Kurla Complex, Bandra (East), MUMBAI - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and ‘ ’ Disclosure Requirements) Regulations, 2015 ( Listing Regulations ).

Vide letter dated September 11, 2023, we had informed the Exchange as regards Lupin Limited (‘the Company’) having planned to enter into a Business Transfer Agreement (‘BTA’) with Lupin Manufacturing Solutions Limited (‘LMSL’), wholly owned subsidiary of the Company, to carve out two Active Pharmaceutical Ingredients manufacturing sites situate at Dabhasa and Visakhapatnam and select R&D operations, including fermentation, at Lupin Research Park, Pune.

We are now pleased to inform you that today i.e. October 16, 2023, the Company has entered into a BTA with LMSL in connection with the carve out.